
    
      Participants will receive BIVV001 once weekly for a total of at least 100 exposure days to
      BIVV001 (including exposure during a BIVV001 parent study, if applicable). Participants will
      have the opportunity to continue in this study for up to 4 years, unless BIVV001 is
      commercially available in their applicable participating country.
    
  